Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in ...
ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal ...
The recommended minimum efficacious dose for the treatment of clinical manifestations of atopic dermatitis in dogs is 1 mg/kg, which can be repeated monthly. Cytopoint will be available in single dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback